Jun. 6 at 11:03 AM
$MRUS I strongly recommend that your CEO Bill Lundberg speak with Frank at
$PDSB to learn specifically about HPV16+
HNSCC. If not Frank, he can speak to other experts in the field regarding HPV16+ cancers and how they differ from other subsets of HPV+ HNSCC. Bill may need to temper his enthusiasm a bit and give some credit to the people at PDSB with their
$65M market cap. He touches his heart a lot and seems to care very much for patients. Would he choose his drug trial for a loved one with an HPV16+ malignancy?
Stick to HPV negative tumors Bill. There is enough room in the space for both companies to be successful.